News
1h
Zacks Investment Research on MSNBAYRY Skyrockets 62.9% YTD: Should You Buy or Sell the Stock?The going has been good for the German pharmaceutical giant Bayer BAYRY this year. Shares have surged 62.9% year to date ...
More than just health care for the wealthy, this Bay Area clinic is part of a lucrative and growing industry that sells ...
A large Department of Veterans Affairs cohort study revealed key racial differences in genomic alterations among men with metastatic prostate cancer.
Kairos Pharma shares were higher as the company reported positive safety results from a clinical trial of ENV-105, or carotuximab, in patients with metastatic castration-resistant prostate cancer.
Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85% ...
Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests ...
Explore more
Remember, you can cast your vote once per day, every day, through July 31st for who you believe should be named the 2025 ...
Robert Crane, the founder of Bob’s Bikes for Needy Kids, passed away after a battle with prostate cancer, leaving behind a ...
A clinical trial is launching to test the effectiveness of new tests that aim to detect genetic signatures of cancer in the ...
A Flinders University study shows that bowel cancer survivors face an elevated risk of developing multiple primary cancers ...
Men diagnosed with nonmetastatic low- and intermediate-risk prostate cancer up to 6 times more likely to die of other causes.
Prostate cancer is the most common cancer in Australian men, often detected through PSA blood tests. New guidelines suggest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results